2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Date

Thursday, April 30, 2020

6:00PM-7:00PM: Abstract Number: 042

Safety Analysis of Infliximab-dyyb as Compared to Infliximab in Pediatric Rheumatic Conditions

Poster Session 1

6:00PM-7:00PM: Abstract Number: 064

The First 18 Months of a Pediatric Rheumatology Service at a Tertiary Referral Hospital in Kenya

Poster Session 1

6:00PM-7:00PM: Abstract Number: 070

The Importance of the Patient Global Health Assessment of Disease Activity in Polyarticular Juvenile Idiopathic Arthritis

Poster Session 1

6:00PM-7:00PM: Abstract Number: 150

The Killer Immunoglobulin-like Receptor KIR3DL1 in Combination with HLA-Bw4 Is Associated with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

Poster Session 1

6:00PM-7:00PM: Abstract Number: 057

Transition from Pediatric to Adult Rheumatology: The Clinician as a Fundamental Ally

Poster Session 1

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

2020 Pediatric Rheumatology Symposium

Thursday, April 30, 2020

Safety Analysis of Infliximab-dyyb as Compared to Infliximab in Pediatric Rheumatic Conditions

The First 18 Months of a Pediatric Rheumatology Service at a Tertiary Referral Hospital in Kenya

The Importance of the Patient Global Health Assessment of Disease Activity in Polyarticular Juvenile Idiopathic Arthritis

The Killer Immunoglobulin-like Receptor KIR3DL1 in Combination with HLA-Bw4 Is Associated with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

Transition from Pediatric to Adult Rheumatology: The Clinician as a Fundamental Ally